NCT03780972View on ClinicalTrials.gov

A Study to Evaluate the Safety and Tolerability of ONL1204 in Patients With Macula-off, Rhegmatogenous Retinal Detachment

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

October 21, 2019

Primary Completion Date

August 24, 2021

Study Completion Date

August 24, 2022

Conditions
Rhegmatogenous Retinal Detachment - Macula Off
Interventions
DRUG

ONL1204

Administration of ONL1204 - inhibitor of Fas(CD95) signaling by intravitreal injection

PROCEDURE

Intravitreal Injection

Injection of study drug into the eye

PROCEDURE

Collection of ocular fluids

vitreous and aqueous fluid collection by a tap and during vitrectomy

Trial Locations (4)

2000

Save Sight Institute, Sydney Eye Hospital, Sydney

3002

Royal Adelaide, Melbourne

4101

Queensland Eye Institute, Melbourne

VIC 3002

Center for Eye Rearch Australia, Melbourne

Sponsors

Lead Sponsor

ONL Therapeutics
All Listed Sponsors
lead

ONL Therapeutics

INDUSTRY

NCT03780972 - A Study to Evaluate the Safety and Tolerability of ONL1204 in Patients With Macula-off, Rhegmatogenous Retinal Detachment | Biotech Hunter | Biotech Hunter